You are Trying to View a Free Article

Daily News You Can't Find Anywhere Else

Bharat Biotech's Genome Valley Plant to Churn Out One Billion Doses of Washington University's Intranasal COVID-19 Vaccine, an Industrial Info Market Brief

default

Industry Segment: Market Brief | Word Count: 165 Words
Attachment: Map

Indian bio-pharma major Bharat Biotech International Limited (BBIL) announced it would be manufacturing up to a billion doses of a single-dose intranasal COVID-19 vaccine in collaboration with the Washington University School of Medicine in St Louis, Missouri. According to the company, this novel chimp-adenovirus vaccine candidate - "ChAd-SARS-CoV-2-S," has shown unprecedented levels of protection in mice studies. Besides India's native COVID-19 vaccine "Covaxin," BBIL already is working on another intranasal vaccine - "Coroflu."

Phase I trials for the vaccine would take place in Saint Louis University's Vaccine and Treatment Evaluation Unit. BBIL, upon obtaining the required regulatory approval, would pursue further stages of clinical trials in India. On successful trial, BBIL would undertake large-scale manufacturing of the vaccine at its GMP facility at Genome Valley near Hyderabad city in Southern India.

Industrial Info is tracking 67 active COVID-19 related projects, worth over $393 million, in India.

Subscribe Now! All Fields Required...

Standard Membership - Free